#	Pagina
attuale pagina	/open-h2020/projects/215857/index.html

Opendata, web and dolomites

PFS SIGNED

A cost- energy-efficient treatment technology to remove pharmaceutical pollutants from water

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

PFS project word cloud

Explore the words cloud of the PFS project. It provides you a very rough idea of what is the project "PFS" about.

antibiotics modern biological stability validate mandatory enzyme serious installed successful trial resistant filtration native size revenue total removing medicines 25bn pollutants drugs infrastructure ph 34m investments roll enzymes chemicals therapeutic energy times public natural prescription industrialize 07m pharem validated pharmaceuticals hormone globally efficient plants contribution prepare compact requested water upcoming counter markets drinking legislation disruptors urban pfs first patented bisphenol ec widely alternative 200 compounds temperature designed 2020 litres synthetic posing easily threats purification commercial yearly found organic levels veterinary supply facilities market brings day treatment health feasibility 100bn wastewater active solution deploy run 2015 removal modified biotech

Project "PFS" data sheet

The following table provides information about the project.

Coordinator	PHAREM BIOTECH AB Organization address address: LEVERTINSGATAN 30-1202 city: UPPSALA postcode: 754 30 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Sweden [SE]
Project website	https://www.pharem.se/wastewater-2/
Total cost	2˙962˙500 €
EC max contribution	2˙073˙750 € (70%)
Programme	1. H2020-EU.3.5. (SOCIETAL CHALLENGES - Climate action, Environment, Resource Efficiency and Raw Materials) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
Code Call	H2020-SMEINST-2-2016-2017
Funding Scheme	SME-2
Starting year	2018
Duration (year-month-day)	from 2018-03-01 to 2020-06-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	PHAREM BIOTECH AB PHAREM BIOTECH AB Organization address address: LEVERTINSGATAN 30-1202 city: UPPSALA postcode: 754 30 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (UPPSALA)	coordinator	2˙073˙750.00

Map

Project objective

Widely used pharmaceuticals (synthetic or natural chemicals found in prescription medicines, over-the-counter therapeutic drugs & veterinary drugs) are finding their way into the drinking water supply via wastewater treatment facilities, posing serious threats to public health globally. The problem is that modern wastewater treatment facilities are not designed for effective removal of pharmaceuticals or similar organic compounds. Upcoming EU legislation will make such removal mandatory. Pharem Biotech brings to market PFS—the first patented enzyme-carrying filtration system capable of removing a large range of organic pollutants (pharmaceuticals and other biological active compounds such as bisphenol A, antibiotics, hormone disruptors, etc.). PFS is a filtration solution that can be easily installed at most of wastewater treatment facilities. Its compact size makes it particularly useful for urban wastewater treatment plants. PFS is based on modified enzymes which are 200 times more effective than native enzymes, resistant to low temperature, resistant to low pH and with high levels of stability and activity. Compared to alternative purification methods, PFS is very cost-efficient, and requires no energy to run. As the total EU yearly investments in its wastewater treatment facilities and related infrastructure are expected to reach €25bn per year in 2015-2020, Pharem Biotech is addressing the market of 70,000 facilities in EU processing 100bn litres of water per day in total. During a successful Phase 1 project, Pharem Biotech validated the market and commercial feasibility of PFS, and selected the trial cases to validate the technology as well as key target markets to approach. In this Phase 2 project Pharem Biotech will industrialize PFS, validate it in trial cases and prepare for commercial roll out with the objective is to deploy 50 PFS systems before 2020 and reach revenue of €34m. The requested EC contribution is €2.07m.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PFS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PFS" are provided by the European Opendata Portal: CORDIS opendata.